Meta-Analysis on Randomized Controlled Trials of Vaccines with QS-21 or ISCOMATRIX Adjuvant: Safety and Tolerability

Open Access

Peer-reviewed

Research Article

Emilia Bigaeva ,

* E-mail: e.bigaeva@rug.nl

Affiliation Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, The Netherlands
⨯
Eva van Doorn,

Affiliation Department of Pharmacy, Unit of PharmacoEpidemiology & PharmacoEconomics (PE2), University of Groningen, Groningen, The Netherlands
⨯
Heng Liu,

Affiliation Department of Pharmacy, Unit of PharmacoEpidemiology & PharmacoEconomics (PE2), University of Groningen, Groningen, The Netherlands
⨯
Eelko Hak

Affiliation Department of Pharmacy, Unit of PharmacoEpidemiology & PharmacoEconomics (PE2), University of Groningen, Groningen, The Netherlands
⨯

Reader Comments (0)

Vaccine development
Is the Subject Area "Vaccine development" applicable to this article?

Thanks for your feedback.
Vaccines
Is the Subject Area "Vaccines" applicable to this article?

Thanks for your feedback.
Immunologic adjuvants
Is the Subject Area "Immunologic adjuvants" applicable to this article?

Thanks for your feedback.
Metaanalysis
Is the Subject Area "Metaanalysis" applicable to this article?

Thanks for your feedback.
Pain
Is the Subject Area "Pain" applicable to this article?

Thanks for your feedback.
Randomized controlled trials
Is the Subject Area "Randomized controlled trials" applicable to this article?

Thanks for your feedback.
Medical risk factors
Is the Subject Area "Medical risk factors" applicable to this article?

Thanks for your feedback.
Antigens
Is the Subject Area "Antigens" applicable to this article?

Thanks for your feedback.